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Improvements in the management of acute myocardial infarction together with population aging have made heart failure a growing burden to health care. This improved management originates from an optimized clinical approach to acute coronary syndromes and the efficacy of percutaneous coronary intervention (PCI). Both factors have contributed to the reduction of acute mortality in patients faced with ST-segment elevation myocardial infarction (STEMI). 1 In this setting, a challenge has arisen in identifying those patients who are at risk of progressive adverse remodeling and myocardial dysfunction. This challenge now constitutes one of the driving forces in cardiovascular clinical research.
Parallel to this development, the arsenal of noninvasive imaging techniques at our disposal has been expanded by the development of cardiac PET and cardiac MR (CMR), which are powerful non-invasive imaging techniques conveying complementary (patho)-physiological and anatomical characterization. However, since many different measurements can be performed with these techniques, which one should be applied? For instance, ''list-mode'' acquired PET can evaluate myocardial perfusion (reserve) in relative or absolute terms, as well as ventricular function. CMR is able to document the presence of scar tissue (through late gadolinium enhancement [LGE]), myocardial perfusion (through the use of gadolinium in the first pass), and even tissue edema (through T2-weighted imaging), while providing accurate functional evaluation (through cine imaging) of the myocardium in the form of ventricular dimensions and ejection fraction, as well as wall motion and thickening.
With this in mind, a number of studies have demonstrated that deteriorating ventricular dimensions (known as adverse remodeling) and function after a hard event, such as STEMI, constitute important predictors of the risk for developing major adverse cardiovascular events, including cardiac death and heart failure.
2 These studies, however, have been performed after a stabilization period of weeks or months, and our understanding of early (subacute) predictors of adverse remodeling is still incomplete.
In the current issue of the Journal of Nuclear Cardiology, Ghotbi and colleagues propose rest 82 Rb PET imaging for the evaluation of myocardial perfusion in the subacute (early) phase after a PCI-treated STEMI, and evaluate its predictive relationship with ulterior CMRassessed ventricular remodeling and function after 3 months. 3 Although a relatively small number of patients were examined (35 subjects), their study is a valuable investigation. PET myocardial perfusion imaging has proven to have superior image quality to SPECT, and it represents the current reference standard to quantify myocardial blood flow, 4 both globally and segmentally. PET has constitutional advantages over SPECT such as constitutional attenuation correction, higher spatial resolution, and better image contrast. The availability of fast photomultipliers, high-density scintillators, modern electronics, and faster computational capabilities, including time-of-flight systems, has made it possible to optimize perfusion imaging. 5 Thus, PET provides the best option for accurately characterizing the myocardial perfusion status. Because of the clinical setting of the study by Ghotbi et al, PET was performed only during rest for reasons of safety in order to refrain patients from undergoing a pharmacological stress test. Thus, the traditional two-phase PET perfusion scan (which allows for myocardial perfusion reserve evaluation) and the regionally proposed stress-only approach 6 were not applied. Nevertheless, this rest-only scanning can be of interest as a particular application of cardiac PET, since it has the additional advantage of a reduced radiation dose and therefore, warrants further research. However, additional insight into the influence of well-known factors that influence myocardial blood flow at rest (e.g., hypertension and gender) 7 is mandatory. An interesting feature in gated cardiac PET is that it allows the reconstruction of ECGgated datasets for simultaneous functional analysis that provides adequate wall motion scores as well as left ventricular volume and ejection fraction (LVEF). In fact, it has been documented that the prognostic value of 82 Rb-PET for all-cause mortality can be enhanced, by adding PET-measured LVEF data. 8 Hence, the parallel evaluation of both myocardial perfusion and function with PET early after STEMI should also be considered 9 for optimal assessment of myocardial viability.
The main contribution of this Danish study is the documented predictive link between segmental PET perfusion findings, at a median of 36 hours after PCI, and CMR functional and morphological parameters at follow-up. 3 In particular, the extent of the relative perfusion defect (as a surrogate for area of infarction) was significantly associated with ventricular function measured by wall thickening (b = -0.36, P = .001) and LGE (b = 0.43, P = .001), and, to a smaller degree, with wall motion (b = -0.04, P = .001) after 3 months. Similar results were found for absolute myocardial blood flow (wall thickening: b = 39.6, P = .001; LGE: b = 4.6, P = .001; wall motion: b = -38.4, P = .001). In terms of remodeling (ventricular morphology) at follow-up, the extent of the perfusion defect was correlated with LVEF (at the expense of end-systolic volume) and final infarct size (r = -0.53 and r = 0.58, respectively). However, these correlations were considerably moderate compared with absolute myocardial blood flow (r = 0.41 and r = -0.32). Whether the timing of PET imaging, the variation in ventricular segmentation, differences in the medication received (as only one-third of the patients used ACE inhibitors or ARAs at follow-up), or residual microvascular dysfunction and stunning (as pointed out by the authors) may play a role in weakening the aforementioned correlations, is a matter that should encourage future research and discussion.
Ghotbi et al utilized 82 Rb as a perfusion agent. 3 Although myocardial perfusion can be quantified with this radiotracer, it has been demonstrated that the kinetics of 82 Rb lead to underestimation of myocardial blood flow at higher flow values due to a marked roll-off effect. 10 Therefore, it is likely that the application of alternative tracers with more favorable extraction profiles, such as 13 N-ammonia and 15 O-water, could enhance the prognostic value of PET measurements of myocardial perfusion at rest in forecasting CMR-evaluated wall motion abnormalities and scar extension. [11] [12] [13] [14] It is true, as the authors correctly state, that 82 Rb offers the important advantage of independence from an onsite cyclotron. However, 13 N-ammonia-and 15 O-waterproducing ''baby'' cyclotrons are now commercially available and offer new opportunities. Dedicated software programs should also be taken into consideration for calculation of reliable all-purpose cut-off perfusion values, because of the intrinsic variability between tracers and different camera systems. 15 Finally, the costs and investments related to PET imaging, as well as existing reimbursement policies, have represented constant challenges to the development and refinement of the clinical implementation of cardiac PET. In the future, when the practical utility and costeffectiveness of PET imaging have been demonstrated, further clinical implementation can be expected. Measurement of myocardial perfusion early post-STEMI may be one of the candidates for such implementation and further evidence for the clinical value of this technique is definitely desired.
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